Symbiotic.blue, a UK-based Techbio company is innovating a next-generation artificial intelligence-driven drug discovery (AIDD) platform that combines the power of generative AI with brain-inspired methodologies. The company's platform integrates two groundbreaking technologies: Hierarchical Feature Binding (HFB), which is inspired by the human brain's information processing to allow AI to model biology contextually, and Unimolecular Polypharmacy (UniMP), which generates molecules that can simultaneously target multiple biological pathways, enhancing efficacy and reducing development risks. Symbiotic.blue is developing a platform and pipeline in parallel, beginning with obesity, in order to prioritise clinical validation, and is currently raising a pre-seed financing round to build its proprietary platform and initiate early-stage discovery programs.